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Abstract
Prospective cohort studies have provided some evidence that circulating vitamin D is associated 
with risk of, and survival from renal cell carcinoma (RCC), but it is unclear whether 
concentrations of vitamin D at the time of diagnosis of renal cell RCC is associated with 
prognosis. We conducted a case-cohort study of 630 RCC cases, including 203 deaths) from a 
multi-centre case-control study in Eastern Europe. Vitamin D was assessed as 25-hydroxyvitamin 
D3 [25(OH)D3], and we used weighted Cox models to estimate hazard ratios (HR) and 95% 
confidence intervals (CI) by categories of season-adjusted 25(OH)D3. Higher concentrations of 
25(OH)D3 were associated with lower risk of death after adjusting for stage, age, sex, and country 
(HR highest versus lowest category 0.57, 95% CI [0.34, 0.97]). The inverse associations of 
25(OH)D3 with death were most notable among those who died from non-RCC causes and those 
diagnosed with early stage disease. In summary, 25(OH)D3 concentration at diagnosis of RCC 
was inversely associated with all-cause mortality rates, but not specifically with RCC outcome.
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Introduction
Each year more than 300,000 new cases of kidney cancer are diagnosed worldwide, leading 
to approximately 130,000 deaths [1]. The prognosis is strongly dependent on stage at 
diagnosis, with around 90% of stage I patients alive five years after diagnosis, compared 
with only 10% of stage IV patients [2].
Little is known about factors influencing survival after diagnosis of kidney cancer, apart 
from tumor stage and grade. We recently investigated circulating vitamin D and kidney 
cancer onset and survival in a prospective epidemiological cohort where blood samples were 
collected at entry to the cohort, an average of 7 years before diagnosis [3]. In contrast to the 
Vitamin D Pooling Project, which found no evidence of an association [4], we reported an 
inverse association between vitamin D concentrations and risk of subsequent kidney cancer. 
This observation was consistent with another recent study in which investigators had 
estimated vitamin D levels [5]. Further, we observed an increased rate of death after kidney 
cancer diagnosis for both low and high concentrations of vitamin D. Available data did not 
allow thorough analysis of cause-specific mortality, nor were we able to adjust for stage. 
This observation prompted us to investigate whether vitamin D concentrations in blood at 
kidney cancer diagnosis are associated with subsequent survival, and if such an association 
is independent of stage or other prognostic factors.
Materials and Methods
The K2 study
Participants included patients who were above 18 years of age and diagnosed with kidney 
cancer in one of 4 participating centres in Czech Republic, 1 center in Romania, and 1 center 
in Russia. We gave participants a standardized face-to-face short lifestyle questionnaire 
covering socio-demographic characteristics, anthropometric measures, medical history, 
family history, and tobacco and alcohol use. Clinical and pathological data were abstracted 
from medical charts and pathological reports. A majority of participants underwent 
nephrectomy and the tumor was histologically confirmed. Follow-up for outcome (relapse, 
vital status, and cause of death where relevant) was performed every 6 to 12 months after 
diagnosis, using passive follow-up methods where possible (with confirmation of vital status 
through active follow-up methods in case of uncertainties), and active follow-up methods 
when no linkage to databases was possible. The study protocol was approved by the 
institutional review boards of the International Agency for Research on Cancer and all 
collaborating institutions, and we obtained written informed consent from all participants.
Case-cohort sampling
Among 2330 participants with questionnaire data available and a diagnosis of renal cell 
carcinoma (RCC) 1005 participants with no follow-up data at the time of this project were 
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excluded. The majority of the cases with no follow-up for vital status were diagnosed at the 
end of the study period, and thus were not included in the active follow-up to ascertain vital 
status. In addition, patients diagnosed in Moscow hospitals who are not resident in the 
Moscow area were not followed-up, nor were patients diagnosed in Serbia. We additionally 
excluded 125 participants with no plasma sample available, 5 participants with 
inconsistencies in reference dates, and 7 participants with no information on stage. From the 
1188 remaining, we randomly selected 500 participants at baseline (the subcohort). We also 
included all participants who died during follow-up that were not randomly selected in to the 
subcohort (N=93), as well as 37 stage IV patients that had survived and were not randomly 
selected. Hence a total of 630 participants diagnosed with kidney cancer were included in 
the study. Median follow-up of the randomly selected subcohort was 2.5 years. The 
demographic and clinical characteristics of the cohort did not differ substantially between 
those included in or excluded from the case-cohort sample (Supplementary Table 1).
Biosample processing and biochemical analysis
Venous blood was obtained before or at the time of the nephrectomy, prior to any treatment. 
Blood was collected in vacutainers containing ethylenediaminetetraacetic acid (EDTA), and 
processed as rapidly as possible (usually within two hours). Plasma samples were stored at 
−80°C, except in Ceske Budejovice, Czech Republic, where samples were stored at −20°C. 
All samples were transported at −80°C to IARC for long-term storage at −150°C. Samples 
underwent a single thawing cycle for aliquoting of 400μL for shipment to the Bevital 
laboratory in Bergen, Norway (www.bevital.no), for analysis. Liquid chromatography 
coupled to tandem mass spectrometry was used to analyse vitamin D as 25(OH)D2 and 
25(OH)D3 [6]. 25(OH)D2 was undetectable in the majority of samples, so our analyses 
focus on 25(OH)D3. The lab is DEQAS (www.deqas.org) certified.
Statistical analysis
To adjust for seasonal variation, we modeled the expected log2 25(OH)D3 concentration as a 
periodic function of day of blood draw using a pair of sine and cosine functions. To create 
season-adjusted categories, we grouped the residuals from this model at quartiles of their 
distribution among the randomly selected subcohort. We used Cox proportional hazards 
models with time since diagnosis (recruitment) as the time scale to estimate hazard ratios 
(HR) and 95% confidence intervals (CI) for all-cause mortality by the season-adjusted 
categories of 25(OH)D3. We also modeled 25(OH)D3 continuously using restricted cubic 
splines with knots at its 10th, 33rd, 67th, and 90th percentiles, explicitly adjusting for 
seasonality by including the pair of sine and cosine functions. HRs for cause-specific 
mortality were calculated in a competing risks model using the data augmentation method 
[7]. To account for the case-cohort design [8], we used Barlow’s method to weight the 
likelihood and computed robust variance estimates [9, 10], slightly adjusted to account for 
the fact that we included all cases with stage IV disease (i.e., all stage IV cases received a 
weight of 1). We investigated potential effect modification by fitting interactions between 
season-adjusted log2 25(OH)D3 and various factors. All models included stage, age at 
recruitment, and sex as covariates, with the baseline hazard stratified by country of 
recruitment. We additionally adjusted for body mass index (BMI, kg/m2), smoking status 
(never, former, current), and alcohol drinking status (never, former, current). All p-values 
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are two sided, and were calculated using the Wald test. Statistical analyses were performed 
using Stata 12.1 for Linux (Stata Corporation, College Station, Texas, US) and R version 
3.1.1 [11].
Results
Demographic and clinical characteristics of the study sample by vital status at the end of 
follow-up are presented in Table 1. The sample included a higher proportion of men (63%) 
than women, and was predominantly recruited from the Czech Republic (52%) and Russia 
(43%), with only 5% or participants recruited in Romania. Those participants who survived 
to the end of follow-up had a similar age distribution to those who died during follow-up. 
518 of the 630 cases (82%) were conventional RCC. 50% of the 203 deaths occurred among 
participants with a stage IV tumor, and 15% of those surviving to the end of follow-up had 
stage IV diagnoses. In contrast, 72 % of those surviving to the end of follow-up were 
diagnosed with stage I–II disease. Measured 25(OH)D3 concentrations ranged between 7 
and 134 nmol/L, with a median of 43 nmol/L.
Hazard of death from any cause was inversely associated with circulating concentrations of 
25(OH)D3 (Table 2). After adjusting for stage, age, and sex, the hazard was 43% lower 
among those in the highest compared to the lowest group of seasonally-adjusted 
concentration (HR4vs1 0.57, 95% CI [0.34, 0.97]). Although no statistical evidence for 
heterogeneity by cause of death was noted (Pheterogeneity 0.53), we estimated HR4vs1 of 
0.70 (95% CI 0.39, 1.24) for RCC specific death, and 0.36 (95% CI 0.14, 0.91) for non-RCC 
causes of death, suggesting that this association was not specific to RCC death (Table 2). 
The HR for continuously varying 25(OH)D3 (relative to a concentration of 50 nmol/L) is 
presented in Figure 1. These estimates corroborate those in Table 2, suggesting a monotonic 
inverse association between 25(OH)D3 and hazard of death.
Supplementary Figure 1 presents HRs for a doubling in seasonally adjusted 25(OH)D3 
concentration separately by categories of several potential effect modifiers. The estimated 
magnitude of the association was consistent by sex, stage, histology, history of diabetes, 
smoking status, and alcohol intake status. There was some indication that the association 
might be stronger among those diagnosed at age 65 years or older, those with a history of 
hypertension, those with higher BMI, and those diagnosed with stage I or II RCC, but there 
was little statistical evidence of interaction with any of these factors.
Discussion
We investigated whether differences in circulating concentrations of 25(OH)D3 at the time 
of diagnosis of RCC were associated with all-cause and RCC-specific survival. We observed 
that higher concentrations of 25(OH)D3 were associated with a lower rate of death, but that 
this association was not restricted to RCC specific death. We also observed an indication 
that this association might be somewhat stronger for those with a history of hypertension, 
advanced age at diagnosis, or early stage disease.
We recently studied circulating 25(OH)D3 and risk of RCC in a prospective case-control 
study nested within the EPIC cohort [3]. This analysis indicated an inverse association 
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between 25(OH)D3 and risk of RCC as well as a non-linear U-shaped association between 
pre-diagnostic 25(OH)D3 and all-cause mortality after diagnosis of RCC. This observation 
prompted us to conduct the current analysis in newly diagnosed RCC cases with complete 
information on disease stage and cause of death. Results from the present study are not 
completely consistent with these initial findings from EPIC. In particular, we found no 
evidence of increased rate of death among patients with high 25(OH)D3 at diagnosis, but 
rather an inverse association between 25(OH)D3 and all-cause mortality across the range of 
observed concentrations.
Many studies have investigated circulating vitamin D and all-cause mortality in general 
populations. Consistent with our observation, many of these have reported high risk of death 
for people with low concentrations [12–19], suggesting that the association observed in our 
study might reflect a general phenomenon rather than something specific to RCC prognosis. 
This would be consistent with our observation that any association might be stronger among 
those patients diagnosed with early rather than advanced stage tumours. The lack of 
heterogeneity by cause of death provides additional indirect evidence that the association 
between vitamin D and mortality is unlikely to exist exclusively among RCC patients.
Circulating vitamin D (measured as 25(OH)D3 in the current study) is converted to its to its 
active hydroxilated form calcitriol (1,25(OH)D3) in the kidneys. Calcitriol is a potent steroid 
hormone that has been implicated by in vitro and in vivo models as having anti-cancer 
influence in a wide range of cancers by affecting multiple cancer hallmarks, including 
reducing angiogenesis, metastasis, cell invasion, inflammation and proliferation, as well as 
stimulating apoptosis [20], and through these mechanisms higher concentrations of 
circulating vitamin D may inhibit tumour progression leading to improved survival. In 
addition, it is possible that kidney function is affected by the presence of the tumour, which 
may lead to disregulation of the conversion of circulating vitamin D to calcitriol. The effects 
of such disregulation on any causal association between vitamin D and RCC prognosis are 
difficult to predict. Given that we observe no evidence of heterogeneity by cause of death, 
we tentatively infer that circulating vitamin D is not causally associated with RCC tumour 
progression and prognosis, but is rather an indicator of general health status.
One limitation of our study is that we were unable to adjust for grade, which was 
unavailable for a substantial proportion (28%) of participants. Nevertheless, given that our 
results do not differ by cause of death, we consider it unlikely that tumour grade is an 
important confounder or effect modifier. Another limitation of our study is that we did not 
have information regarding the use of vitamin D supplements, though it is unlikely that 
supplement use was highly prevalent given that 25(OH)D2 concentrations were undetectable 
for the majority of participants. It is also possible that these results may not generalise 
beyond Central and Eastern European populations, but the remarkable consistency with 
results observed in non-clinical cohort studies suggests that that our results will generalise 
well, at least to a broader population of European origin.
In summary, we found that high 25(OH)D3 at diagnosis of RCC was associated with lower 
risk of death. This association was not restricted to RCC cause-specific death, and appeared 
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stronger for early stage disease, supporting the notion of 25(OH)D3 being associated with 
lower overall death rates in general, rather than RCC prognosis specifically.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Hazard ratio for all cause mortality among RCC cases as a function of circulating 
concentration of 25(OH)D3 at diagnosis, relative to a concentration of 50 nmol/L. 25(OH)D3 
was modeled using restricted cubic splines with knots at the 10th, 33rd, 67th, and 90th 
percentiles of its distribution. Estimates were derived from a Cox model stratified by 
country of recruitment, and adjusted for stage, age at recruitment, sex, and seasonality (sine 
and cosine functions of day of blood draw). Solid and dashed lines represent the maximum 
pseudolikelihood estimates and 95% confidence intervals respectively. The translucent lines 
are 1000 draws from the multivariate normal distribution defined by the maximum 
pseudolikelihood estimates and their variance covariance matrix, and thus give an indication 
of the posterior density for the hazard ratio under a uniform prior on the regression 
coefficients. The “rug plot” shows the observed distribution of 25(OH)D3.
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